CVE:BCTBriacell Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Briacell Therapeutics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add C$6.10 0.00 (0.00 %) (As of 07/3/2020 04:00 PM ET) Add Compare Share Today's RangeC$6.10Now: C$6.10▼C$6.1050-Day RangeC$6.10MA: C$9.01▼C$10.3952-Week RangeC$6.10Now: C$6.10▼C$27.00VolumeN/AAverage Volume961 shsMarket CapitalizationC$4.40 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsEarningsInsider TradesHeadlinesSocial Media BriaCell Therapeutics Corp., an immuno-oncology focused biotechnology company, develops personalized treatments for cancer. Its lead product candidate is Bria-IMT, a clinical trial in combination with pembrolizumab (KEYTRUDA; manufactured by Merck & Co., Inc.) for use in patients with breast cancer. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer patients; and BriaDX, its companion diagnostic test. Its preclinical small molecule program consists of protein kinase C delta inhibitors for cancer and fibrotic diseases. BriaCell Therapeutics Corp. has a clinical trial collaboration and supply agreement with Incyte Corporation for developing Bria-IMT with compounds for treating breast cancer. The company is headquartered in West Vancouver, Canada.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Briacell Therapeutics. Previous Next 2.7 Community Rank Outperform VotesBriacell Therapeutics has received 40 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBriacell Therapeutics has received 34 “underperform” votes. (Add your “underperform” vote.)Community SentimentBriacell Therapeutics has received 54.05% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Briacell Therapeutics and other stocks. Vote “Outperform” if you believe BCT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BCT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBriacell Therapeutics does not currently pay a dividend.Dividend GrowthBriacell Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Briacell Therapeutics insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Briacell Therapeutics is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Briacell Therapeutics is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.54 out of 5 stars Industry, Sector and Symbol Stock Exchange CVE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolCVE:BCT Previous Symbol CUSIPN/A CIKN/A Webwww.briacell.com Phone+1-604-9211810Debt Debt-to-Equity Ratio48.40 Current Ratio0.08 Quick Ratio0.03Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.10 per share Price / Cash Flow60.62 Book ValueC($4.14) per share Price / Book-1.47Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares722,000Market CapC$4.40 million Next Earnings Date10/27/2020 (Estimated) OptionableNot Optionable TSXV:BCT Rates by TradingView Receive BCT News and Ratings via Email Sign-up to receive the latest news and ratings for BCT and its competitors with MarketBeat's FREE daily newsletter. Briacell Therapeutics (CVE:BCT) Frequently Asked Questions How has Briacell Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Briacell Therapeutics' stock was trading at C$17.80 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BCT shares have decreased by 65.7% and is now trading at C$6.10. View which stocks have been most impacted by Coronavirus. When is Briacell Therapeutics' next earnings date? Briacell Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, October 27th 2020. View our earnings forecast for Briacell Therapeutics. Has Briacell Therapeutics been receiving favorable news coverage? News coverage about BCT stock has trended negative this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Briacell Therapeutics earned a coverage optimism score of -2.4 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about Briacell Therapeutics. Who are some of Briacell Therapeutics' key competitors? Some companies that are related to Briacell Therapeutics include ContraVir Pharmaceuticals (HEPA), Fusion Antibodies (FAB), Bio-Gene Technology (BGT), Tissue Regenix Group (TRX), NovaBay Pharmaceuticals (NBY), Oragenics (OGEN), Bionomics (BNO), Hemogenyx Pharmaceuticals (HEMO), ImmuPharma (IMM), Acrux (ACR), Quest PharmaTech (QPT), Ceapro (CZO), Skinbiotherapeutics (SBTX), Actinogen Medical (ACW) and Exopharm (EX1). View all competitors. What other stocks do shareholders of Briacell Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Briacell Therapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Gene Biotherapeutics (CRXM), Organovo (ONVO), Anavex Life Sciences (AVXL), Actinium Pharmaceuticals (ATNM), Cytokinetics (CYTK), Genmab A/S (GNMSF), Inovio Pharmaceuticals (INO), IsoRay (ISR) and Medidata Solutions (MDSO). Who are Briacell Therapeutics' key executives? Briacell Therapeutics' management team includes the following people: Dr. William V. Williams M.D., CEO, Pres & DirectorDr. Charles Louis Wiseman M.D., FACP, Founder & DirectorMr. Gadi Levin B.Com., C.A., M.B.A., CPA, MBA, CFO & Corp. Sec. (Age 46)Ms. Farrah Dean, Mang. of Corp. Devel. What is Briacell Therapeutics' stock symbol? Briacell Therapeutics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "BCT." How do I buy shares of Briacell Therapeutics? Shares of BCT and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab. What is Briacell Therapeutics' stock price today? One share of BCT stock can currently be purchased for approximately C$6.10. How big of a company is Briacell Therapeutics? Briacell Therapeutics has a market capitalization of C$4.40 million. What is Briacell Therapeutics' official website? The official website for Briacell Therapeutics is www.briacell.com. How can I contact Briacell Therapeutics? Briacell Therapeutics' mailing address is Bellevue Centre, 235 15th St 3rd Floor, WEST VANCOUVER, BC V7T 2X1, Canada. The company can be reached via phone at +1-604-9211810. This page was last updated on 7/5/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
